Advanced search
Publication Cover
OncoTargets and Therapy Volume 16, 2023 - Issue
Submit an article Journal homepage
181
Views
0
CrossRef citations to date
0
Altmetric
CASE REPORT

Gilteritinib Affects the Selection of Dominant Clones in Clonal Hematopoiesis: Sequential Genetic Analysis of an FLT3-ITD Positive AML Patient with Long-Term Gilteritinib Therapy

Seiichiro Katagiri1 Department of Hematology, Tokyo Medical University, Tokyo, JapanCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-3031-9990
ORCID Icon,
Nahoko Furuya1 Department of Hematology, Tokyo Medical University, Tokyo, Japan
,
Daigo Akahane1 Department of Hematology, Tokyo Medical University, Tokyo, Japan
,
SungGi Chi2 Department of Hematology, National Cancer Center Hospital East, Chiba, Japan
,
Yosuke Minami2 Department of Hematology, National Cancer Center Hospital East, Chiba, Japan
,
Yuka Harada3 Department of Clinical Laboratory, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan
,
Hironori Harada4 Laboratory of Oncology, School of Life Sciences, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan
&
Akihiko Gotoh1 Department of Hematology, Tokyo Medical University, Tokyo, Japan
 show all
Pages 571-576 | Received 27 Apr 2023, Accepted 04 Jul 2023, Published online: 12 Jul 2023

References

  • Khoury JD, Solary E, Abla O, et al. The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36(7):1703–1719. doi:10.1038/s41375-022-01613-1
  • Steensma DP, Bejar R, Jaiswal S, et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood. 2015;126(1):9–16. doi:10.1182/blood-2015-03-631747
  • Abelson S, Collord G, Ng SWK, et al. Prediction of acute myeloid leukaemia risk in healthy individuals. Nature. 2018;559(7714):400–404. doi:10.1038/s41586-018-0317-6
  • Yamamoto Y, Kiyoi H, Nakano Y, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood. 2001;97(8):2434–2439. doi:10.1182/blood.V97.8.2434
  • Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209–2221. doi:10.1056/NEJMoa1516192
  • Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med. 2019;381(18):1728–1740. doi:10.1056/NEJMoa1902688
  • Perl AE, Larson RA, Podoltsev NA, et al. Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the Phase 3 ADMIRAL trial. Blood. 2022;139(23):3366–3375. doi:10.1182/blood.2021011583
  • Hosono N, Chi S, Yamauchi T, et al. Clinical utility of genomic profiling of AML using paraffin-embedded bone marrow clots: HM-SCREEN-Japan 01. Cancer Sci. 2023;114(5):2098–2108. doi:10.1111/cas.15746
  • Konishi T, Sadato D, Toya T, et al. Impact of gene alterations on clinical outcome in young adults with myelodysplastic syndromes. Sci Rep. 2023;13(1):2641. doi:10.1038/s41598-023-29794-4
  • Arai H, Chi S, Utsu Y, et al. A practice-oriented genome profiling study with the novel halo-shape annealing and defer-ligation enrichment (HANDLE) system: HM-screen-JAPAN02. Blood. 2022;140(Supplement 1):10722–10724. doi:10.1182/blood-2022-159351
  • Gillis NK, Ball M, Zhang Q, et al. Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study. Lancet Oncol. 2017;18(1):112–121. doi:10.1016/S1470-2045(16)30627-1
  • Wong TN, Ramsingh G, Young AL, et al. Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature. 2015;518(7540):552–555. doi:10.1038/nature13968
  • Sanada M, Suzuki T, Shih LY, et al. Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature. 2009;460(7257):904–908. doi:10.1038/nature08240
  • Dunbar AJ, Gondek LP, O’Keefe CL, et al. 250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies. Cancer Res. 2008;68(24):10349–10357. doi:10.1158/0008-5472.CAN-08-2754
  • McMahon CM, Ferng T, Canaani J, et al. Clonal selection with RAS pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia. Cancer Discov. 2019;9(8):1050–1063. doi:10.1158/2159-8290.CD-18-1453
  • Schnittger S, Bacher U, Alpermann T, et al. Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myelodysplastic/myeloproliferative disorders: an analysis of 636 cases. Haematologica. 2012;97(12):1890–1894. doi:10.3324/haematol.2012.065375

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.